Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

Cell-based immunotherapy approaches for multiple myeloma.

Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H, Müller-Tidow C, Hundemer M.

Br J Cancer. 2018 Dec 6. doi: 10.1038/s41416-018-0346-9. [Epub ahead of print] Review.

PMID:
30518815
2.

Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation.

Radujkovic A, Dai H, Kordelas L, Beelen D, Rachakonda SP, Müller-Tidow C, Kumar R, Dreger P, Luft T.

Haematologica. 2018 Dec 4. pii: haematol.2018.202267. doi: 10.3324/haematol.2018.202267. [Epub ahead of print]

3.

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.

Döhner H, Müller-Tidow C, Lübbert M, Fiedler W, Krämer A, Westermann J, Bug G, Schlenk RF, Krug U, Goeldner RG, Hilbert J, Taube T, Ottmann OG.

Br J Haematol. 2018 Nov 19. doi: 10.1111/bjh.15563. [Epub ahead of print] No abstract available.

PMID:
30450591
4.

Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.

Wang L, Ni M, Hückelhoven-Krauss A, Sellner L, Hoffmann JM, Neuber B, Luft T, Hegenbart U, Schönland S, Kleist C, Sill M, Chen BA, Wuchter P, Eckstein V, Krüger W, Hilgendorf I, Yerushalmi R, Nagler A, Müller-Tidow C, Ho AD, Dreger P, Schmitt M, Schmitt A.

Front Immunol. 2018 Oct 8;9:2207. doi: 10.3389/fimmu.2018.02207. eCollection 2018.

5.

JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia-Letter.

von Bonin M, Moll K, Kramer M, Oelschlägel U, Wermke M, Röllig C, Thiede C, Ehninger G, Krämer A, Müller-Tidow C, Mitroulis I, Bornhäuser M.

Cancer Res. 2018 Nov 1;78(21):6339-6341. doi: 10.1158/0008-5472.CAN-18-0642. Epub 2018 Oct 17. No abstract available.

PMID:
30333115
6.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

7.

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.

Oncoimmunology. 2018 Aug 1;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018.

PMID:
30288348
8.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J.

Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4.

9.

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack.

Schlenk RF, Jaramillo S, Müller-Tidow C.

Haematologica. 2018 Oct;103(10):1579-1581. doi: 10.3324/haematol.2018.200485. No abstract available.

10.

Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products.

Kriegsmann K, Wack M, Pavel P, Schmitt A, Kriegsmann M, Bruckner T, Müller-Tidow C, Wuchter P.

Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30570-6. doi: 10.1016/j.bbmt.2018.09.013. [Epub ahead of print]

PMID:
30244098
11.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Aug 23;174(5):1325. doi: 10.1016/j.cell.2018.08.014. No abstract available.

PMID:
30142347
12.

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.

Plaumann J, Engelhardt M, Awwad MHS, Echchannaoui H, Amman E, Raab MS, Hillengass J, Halama N, Neuber B, Müller-Tidow C, Goldschmidt H, Hundemer M.

Cancer Immunol Immunother. 2018 Nov;67(11):1695-1707. doi: 10.1007/s00262-018-2230-0. Epub 2018 Aug 20.

PMID:
30128739
13.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
14.

MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia.

Hartmann JU, Bräuer-Hartmann D, Kardosova M, Wurm AA, Wilke F, Schödel C, Gerloff D, Katzerke C, Krakowsky R, Namasu CY, Bill M, Schwind S, Müller-Tidow C, Niederwieser D, Alberich-Jorda M, Behre G.

Cell Death Dis. 2018 Jul 26;9(8):814. doi: 10.1038/s41419-018-0837-x.

15.

Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.

Stock S, Hoffmann JM, Schubert ML, Wang L, Wang S, Gong W, Neuber B, Gern U, Schmitt A, Müller-Tidow C, Dreger P, Schmitt M, Sellner L.

Hum Gene Ther. 2018 Oct;29(10):1167-1182. doi: 10.1089/hum.2017.237. Epub 2018 Sep 5.

PMID:
30024314
16.

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.

Bäumer N, Rehkämper J, Appel N, Terheyden L, Hartmann W, Wardelmann E, Buchholz F, Müller-Tidow C, Berdel WE, Bäumer S.

PLoS One. 2018 Jul 12;13(7):e0200163. doi: 10.1371/journal.pone.0200163. eCollection 2018.

17.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Jun 28;174(1):172-186.e21. doi: 10.1016/j.cell.2018.05.048. Erratum in: Cell. 2018 Aug 23;174(5):1325.

18.

appreci8: A Pipeline for Precise Variant Calling Integrating 8 Tools.

Sandmann S, Karimi M, de Graaf AO, Rohde C, Göllner S, Varghese J, Ernsting J, Walldin G, van der Reijden BA, Müller-Tidow C, Malcovati L, Hellström-Lindberg E, Jansen JH, Dugas M.

Bioinformatics. 2018 Jun 26. doi: 10.1093/bioinformatics/bty518. [Epub ahead of print]

PMID:
29945233
19.

BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?

Neuendorff NR, Hemmati P, Arnold R, Ihlow J, Dörken B, Müller-Tidow C, Westermann J.

Blood Adv. 2018 Jun 26;2(12):1409-1411. doi: 10.1182/bloodadvances.2018015594. No abstract available.

20.

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.

Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H.

Br J Haematol. 2018 Jun 8. doi: 10.1111/bjh.15204. [Epub ahead of print] No abstract available.

PMID:
29882583
21.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
22.

CD7 is expressed on a subset of normal CD34-positive myeloid precursors.

Kriegsmann K, Löffler H, Eckstein V, Schulz R, Kräker S, Braun U, Luft T, Hegenbart U, Schönland S, Dreger P, Krämer A, Ho AD, Müller-Tidow C, Hundemer M.

Eur J Haematol. 2018 Sep;101(3):318-325. doi: 10.1111/ejh.13100. Epub 2018 Jul 4.

PMID:
29797671
23.

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.

Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C.

Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22.

PMID:
29654265
24.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Sep;94(5):611-620. doi: 10.1002/cyto.b.21636. Epub 2018 Apr 20.

PMID:
29577600
25.

miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia.

Krakowsky RHE, Wurm AA, Gerloff D, Katzerke C, Bräuer-Hartmann D, Hartmann JU, Wilke F, Thiede C, Müller-Tidow C, Niederwieser D, Behre G.

Blood Cancer J. 2018 Mar 21;8(3):36. doi: 10.1038/s41408-018-0070-y. No abstract available.

26.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

27.

Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation.

Gallitz I, Lofruthe N, Traeger L, Bäumer N, Hoerr V, Faber C, Kuhlmann T, Müller-Tidow C, Steinbicker AU.

BMC Physiol. 2018 Feb 27;18(1):3. doi: 10.1186/s12899-018-0037-z.

28.

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

Hoffmann JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M.

Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017.

29.

Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation.

Rachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A, Müller-Tidow C, Kumar R, Dreger P, Luft T.

J Clin Oncol. 2018 Mar 10;36(8):789-800. doi: 10.1200/JCO.2017.76.4662. Epub 2018 Jan 25.

PMID:
29369699
30.

Obesity is a significant susceptibility factor for idiopathic AA amyloidosis.

Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, Müller-Tidow C, Lorenz HM, Schönland SO.

Amyloid. 2018 Mar;25(1):37-45. doi: 10.1080/13506129.2018.1429391. Epub 2018 Jan 24.

PMID:
29364741
31.

Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow.

Susek KH, Korpos E, Huppert J, Wu C, Savelyeva I, Rosenbauer F, Müller-Tidow C, Koschmieder S, Sorokin L.

Matrix Biol. 2018 Apr;67:47-62. doi: 10.1016/j.matbio.2018.01.007. Epub 2018 Jan 31.

PMID:
29360499
32.

Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection.

Kriegsmann K, Schmitt A, Kriegsmann M, Bruckner T, Anyanwu A, Witzens-Harig M, Müller-Tidow C, Klein S, Wuchter P.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1281-1288. doi: 10.1016/j.bbmt.2018.01.007. Epub 2018 Jan 17.

PMID:
29353110
33.

A new option for remission induction in acute myeloid leukaemia.

Müller-Tidow C, Schlenk RF.

Lancet Oncol. 2018 Feb;19(2):156-157. doi: 10.1016/S1470-2045(18)30012-3. Epub 2018 Jan 12. No abstract available.

PMID:
29339096
34.

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.

Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullerman C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U.

PLoS One. 2018 Jan 2;13(1):e0190802. doi: 10.1371/journal.pone.0190802. eCollection 2018.

35.

ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia.

Namasu CY, Katzerke C, Bräuer-Hartmann D, Wurm AA, Gerloff D, Hartmann JU, Schwind S, Müller-Tidow C, Hilger N, Fricke S, Christopeit M, Niederwieser D, Behre G.

Oncotarget. 2017 Oct 26;8(61):103626-103639. doi: 10.18632/oncotarget.22093. eCollection 2017 Nov 28.

36.

Chimeric antigen receptor transduced T cells: Tuning up for the next generation.

Schubert ML, Hoffmann JM, Dreger P, Müller-Tidow C, Schmitt M.

Int J Cancer. 2018 May 1;142(9):1738-1747. doi: 10.1002/ijc.31147. Epub 2017 Nov 27. Review.

PMID:
29119551
37.

Hematopoietic transcription factors and differential cofactor binding regulate PRKACB isoform expression.

Kuvardina ON, Herkt S, Meyer A, Schneider L, Yillah J, Kohrs N, Bonig H, Seifried E, Müller-Tidow C, Lausen J.

Oncotarget. 2017 Apr 24;8(42):71685-71698. doi: 10.18632/oncotarget.17386. eCollection 2017 Sep 22.

38.

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2017 Sep 8;8(38):64651. doi: 10.18632/oncotarget.20707. eCollection 2017 Sep 8.

39.

Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.

Kayser S, Feszler M, Krzykalla J, Schick M, Kramer M, Benner A, Thol F, Platzbecker U, Müller-Tidow C, Ho AD, Ehninger G, Heuser M, Schlenk RF, Thiede C, Röllig C, Krämer A.

Eur J Haematol. 2017 Dec;99(6):544-552. doi: 10.1111/ejh.12972. Epub 2017 Oct 13.

PMID:
28940816
40.

Successful collection of peripheral blood stem cells upon VIDE chemomobilization in sarcoma patients.

Kriegsmann K, Heilig C, Cremer M, Novotny P, Kriegsmann M, Bruckner T, Müller-Tidow C, Egerer G, Wuchter P.

Eur J Haematol. 2017 Nov;99(5):459-464. doi: 10.1111/ejh.12960. Epub 2017 Oct 10.

PMID:
28884875
41.

Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.

Jordan K, Blättermann L, Hinke A, Müller-Tidow C, Jahn F.

Support Care Cancer. 2018 Jan;26(1):21-32. doi: 10.1007/s00520-017-3857-7. Epub 2017 Aug 31. Review.

PMID:
28861627
42.

Relapsed/refractory acute myeloid leukemia: any progress?

Schlenk RF, Müller-Tidow C, Benner A, Kieser M.

Curr Opin Oncol. 2017 Nov;29(6):467-473. doi: 10.1097/CCO.0000000000000404. Review.

PMID:
28857842
43.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

44.

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.

Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.

45.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
46.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
47.

DDX41-related myeloid neoplasia.

Maciejewski JP, Padgett RA, Brown AL, Müller-Tidow C.

Semin Hematol. 2017 Apr;54(2):94-97. doi: 10.1053/j.seminhematol.2017.04.007. Epub 2017 Apr 21. Review.

PMID:
28637623
48.

Therapy of older persons with acute myeloid leukaemia.

Krug U, Gale RP, Berdel WE, Müller-Tidow C, Stelljes M, Metzeler K, Sauerland MC, Hiddemann W, Büchner T.

Leuk Res. 2017 Sep;60:1-10. doi: 10.1016/j.leukres.2017.05.020. Epub 2017 Jun 1. Review.

PMID:
28618329
49.

Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017. Erratum in: PLoS One. 2017 Aug 9;12 (8):e0183201.

50.

Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.

Schaffrath J, Schmoll HJ, Voigt W, Müller LP, Müller-Tidow C, Mueller T.

PLoS One. 2017 Jun 7;12(6):e0178930. doi: 10.1371/journal.pone.0178930. eCollection 2017.

Supplemental Content

Loading ...
Support Center